Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Biochem Pharmacol. 2014 Nov 7;93(1):85–91. doi: 10.1016/j.bcp.2014.10.014

Table 1.

Activation of Gαi/o, Gβγ, heterologous sensitization, and DMR downstream of the DRD2. Gαi/o signaling and heterologous sensitization were measured in HEK-AC5/D2 cells. Activation of Gβγ signaling was measured in HEK-AC2/D2 cells and DMR was measured in HEK-D2 cells. EC50 values are shown in nM with the 95% confidence interval. The maximal effects are shown as percentages of dopamine’s response with standard errors. Data in the table represent the average of at least three independent experiments. ND = not determined.

Gαi/o activation Gβγ activation Sensitization DMR (AUC)

Compound EC50 (nM) Max (%) EC50 (nM) Max (%) EC50 (nM) Max (%) EC50 (nM) Max (%)
Dopamine 1.5 (0.6–3.7) 100 (±3) 46 (28–75) 100 (±4) 8.2 (5.5–12.2) 100 (±3) 7.6 (6.7–8.6) 100 (±1)
Quinpirole 2.1 (1.0–4.5) 98 (±3) 74 (50–109) 99 (±4) 8.2 (6.1–11.0) 124 (±3) 37 (32–44) 104 (±1)
Aripiprazole 4.1 (0.6–30) 48 (±9) ND - 1.6 (0.7–3.9) 18 (±1) 730 (433–1231) 32 (±1)
Pramipexole 0.9 (0.4–1.9) 87 (±4) 17 (7.7–36) 98 (±5) 1.9 (1.2–3.0) 119 (±4) 8.3 (5.8–12) 98 (±2)
Ropinirole 2.6 (1.1–6.1) 81 (±6) 47 (25–89) 70 (±4) 8.4 (6.1–11.5) 126 (±3) 33 (26–41) 100 (±2)
Rotigotine 0.05 (0.01–0.11) 88 (±4) 0.7 (0.3–1.4) 79 (±4) 0.5 (0.3–0.7) 116 (±5) ND -